New digital scope could help rectal cancer patients avoid surgery

NCT ID NCT06189846

Completed Diagnosis Sponsor: Bordeaux Colorectal Institute Academy Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new digital scope called LUMENEYE to see if it can better measure how much a rectal tumor has shrunk after chemotherapy and radiation. 82 patients who were good candidates for organ preservation were included. The goal was to see if the scope could help doctors decide who can safely skip surgery and keep their rectum.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LUMENEYE rectoscope (a digital endoscope device)
What this could lead to: If successful, this could help doctors more accurately decide which rectal cancer patients can safely avoid surgery and preserve their rectum after chemotherapy and radiation.
What could go wrong: This is a small, completed observational study (82 people) that only measures how well the device agrees with standard tests. It does not test a new treatment or prove long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

Amsterdam UMC

Amsterdam, Netherlands
CHU de ROUEN

Rouen, France
Clinique Tivoli-Ducos - Bordeaux Colorectal Institute

Bordeaux, France
Humanitas Research Hospital

Milan, Italy
Hôpital Européen de Marseille

Marseille, France
Hôpital Saint-Antoine - APHP

Paris, France
Imperial College London

London, United Kingdom
University Hospital Vall D'Hebron

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.